Skip to main content
    M

    Mirum Pharmaceuticals Inc (MIRM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $91.58
    -2.41 (-2.56%)

    Market Cap: $6.14B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Mirum Pharmaceuticals Inc (MIRM) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Mirum Pharmaceuticals are Madrigal Pharmaceuticals (MDGL), Disc Medicine (IRON) and Travere Therapeutics (TVTX). By market cap, Mirum Pharmaceuticals ranks 8th of the 13 companies on this page; Summit Therapeutics (SMMT) is the largest at $11.32B.

    Peer Comparison

    MIRM's ROIC of -133.6% is below the peer median of -23.1%, and its revenue growth of 39.6% is below the median of 43.2%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Mirum Pharmaceuticals (MIRM)$6.14BN/A8.9x-134.7%-133.6%39.6%0.00%
    Madrigal Pharmaceuticals Inc (MDGL)$9.93BN/A8.7x-10.9%-12.7%50.1%0.00%
    Disc Medicine Inc. (IRON)$3.64BN/AN/A0.0%-40.0%0.0%0.00%
    Travere Therapeutics Inc (TVTX)$4.86BN/A7.2x-18.7%-23.1%36.2%0.00%
    Rhythm Pharmaceuticals Inc (RYTM)$7.97BN/A26.4x-69.0%-98.6%79.6%0.00%
    Ligand Pharmaceuticals Incorporated (LGND)$6.18B66.5x23.7x20.3%0.1%-31.8%0.00%
    PTC Therapeutics Inc (PTCT)$5.30BN/A5.2x-9.2%18.1%69.6%0.00%
    Protagonist Therapeutics Inc (PTGX)$8.55B27.7x15.8x62.0%N/A5724.0%0.00%
    Praxis Precision Medicines Inc (PRAX)$9.17BN/AN/A0.0%N/A1349.0%0.00%
    Scholar Rock Holding Corp (SRRK)$5.27BN/AN/A0.0%-89.0%-100.0%0.00%
    Immunovant Inc (IMVT)$7.07BN/AN/A0.0%N/A0.0%0.00%
    Dianthus Therapeutics Inc. (DNTH)$5.17BN/AN/A0.0%N/A205.6%0.00%
    Summit Therapeutics PLC (SMMT)$11.32BN/AN/A0.0%N/A-100.0%0.00%
    Peer median$6.63B47.1x12.2x0.0%-23.1%43.2%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Mirum Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Madrigal Pharmaceuticals Inc (MDGL)
    Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates...
    MDGL competitors
    Disc Medicine Inc. (IRON)
    Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development...
    IRON competitors
    Travere Therapeutics Inc (TVTX)
    Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification...
    TVTX competitors
    Rhythm Pharmaceuticals Inc (RYTM)
    Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment...
    RYTM competitors
    Ligand Pharmaceuticals Incorporated (LGND)
    Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover...
    LGND competitors
    PTC Therapeutics Inc (PTCT)
    PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders.
    PTCT competitors
    Protagonist Therapeutics Inc (PTGX)
    Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical...
    PTGX competitors
    Praxis Precision Medicines Inc (PRAX)
    Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal...
    PRAX competitors
    Scholar Rock Holding Corp (SRRK)
    Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious...
    SRRK competitors
    Immunovant Inc (IMVT)
    Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
    IMVT competitors
    Dianthus Therapeutics Inc. (DNTH)
    Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops...
    DNTH competitors
    Summit Therapeutics PLC (SMMT)
    Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America...
    SMMT competitors

    Frequently Asked Questions About MIRM

    Who are Mirum Pharmaceuticals' main competitors?

    The companies most similar to Mirum Pharmaceuticals include Madrigal Pharmaceuticals (MDGL), Disc Medicine (IRON), Travere Therapeutics (TVTX), Rhythm Pharmaceuticals (RYTM) and Ligand Pharmaceuticals (LGND), listed from the closest match.

    Who is Mirum Pharmaceuticals' biggest competitor?

    Summit Therapeutics (SMMT) is the largest of the similar companies at $11.32B; Madrigal Pharmaceuticals (MDGL) is the closest match by business profile, size, sector and industry.

    How does MIRM stock compare with its competitors?

    MIRM's P/S is 8.9x against a peer median of 12.2x; its net margin is -134.7% against a peer median of 0.0%.

    Which of Mirum Pharmaceuticals' competitors pays a higher dividend?

    Mirum Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Mirum Pharmaceuticals bigger than its competitors?

    No. Mirum Pharmaceuticals is 8th by market cap among the 13 companies on this page; the largest is Summit Therapeutics (SMMT) at $11.32B.